JP2019515025A - トポイソメラーゼ毒 - Google Patents
トポイソメラーゼ毒 Download PDFInfo
- Publication number
- JP2019515025A JP2019515025A JP2019502543A JP2019502543A JP2019515025A JP 2019515025 A JP2019515025 A JP 2019515025A JP 2019502543 A JP2019502543 A JP 2019502543A JP 2019502543 A JP2019502543 A JP 2019502543A JP 2019515025 A JP2019515025 A JP 2019515025A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- compound according
- formula
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C*(C)(C*CCN(C(CCC1)C2)C1CC2OC(Nc1cc(C)ccc1OC)=O)*NC(CCSSc1ccc(COC(C)=O)cc1)=O Chemical compound C*(C)(C*CCN(C(CCC1)C2)C1CC2OC(Nc1cc(C)ccc1OC)=O)*NC(CCSSc1ccc(COC(C)=O)cc1)=O 0.000 description 3
- OILPLPYUXHERBD-UHFFFAOYSA-N CCCNNC(C)CCCO Chemical compound CCCNNC(C)CCCO OILPLPYUXHERBD-UHFFFAOYSA-N 0.000 description 1
- RFJUDNLWFWMYBJ-UHFFFAOYSA-N CN(CCN(C1OC11)c(c(cc2OCOc2c2)c2nc2)c2-c(cc2OC)c1cc2OC)C(OC)=O Chemical compound CN(CCN(C1OC11)c(c(cc2OCOc2c2)c2nc2)c2-c(cc2OC)c1cc2OC)C(OC)=O RFJUDNLWFWMYBJ-UHFFFAOYSA-N 0.000 description 1
- XFDLURJXFNDCPG-UHFFFAOYSA-N CN(CCN(c(c(cc1OCOc1c1)c1nc1)c1-c(cc1OC)c2cc1OC)C2=O)C(C1CCN(C)CC1)=O Chemical compound CN(CCN(c(c(cc1OCOc1c1)c1nc1)c1-c(cc1OC)c2cc1OC)C2=O)C(C1CCN(C)CC1)=O XFDLURJXFNDCPG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662318139P | 2016-04-04 | 2016-04-04 | |
| US62/318,139 | 2016-04-04 | ||
| PCT/US2017/025779 WO2017176648A1 (en) | 2016-04-04 | 2017-04-03 | Topoisomerase poisons |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019515025A true JP2019515025A (ja) | 2019-06-06 |
| JP2019515025A5 JP2019515025A5 (cg-RX-API-DMAC7.html) | 2020-05-14 |
Family
ID=60000629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019502543A Pending JP2019515025A (ja) | 2016-04-04 | 2017-04-03 | トポイソメラーゼ毒 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11091498B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3442979A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2019515025A (cg-RX-API-DMAC7.html) |
| CN (1) | CN109219610A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3019945A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017176648A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109824771B (zh) * | 2019-03-07 | 2020-06-30 | 中国药科大学 | 一种降糖肽及其应用 |
| AU2022216696A1 (en) * | 2021-02-05 | 2023-08-17 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Camptothecin compound, preparation method therefor, and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006065448A2 (en) * | 2004-11-18 | 2006-06-22 | Threshold Pharmaceuticals, Inc. | Topoisomerase inhibitors and prodrugs |
| JP2007514652A (ja) * | 2003-11-06 | 2007-06-07 | シアトル ジェネティックス, インコーポレイテッド | リガンドに結合体化可能なモノメチルバリン化合物 |
| JP2010519310A (ja) * | 2007-02-21 | 2010-06-03 | メダレックス インコーポレイテッド | 単一のアミノ酸を有する化学リンカーおよびその複合体 |
| JP2010526821A (ja) * | 2007-05-08 | 2010-08-05 | ジェネンテック, インコーポレイテッド | システイン改変抗muc16抗体および抗体−薬物結合体 |
| WO2010127363A1 (en) * | 2009-05-01 | 2010-11-04 | Rutgers, The State University Of New Jersey | Toposiomerase inhibitors |
| WO2014164503A1 (en) * | 2013-03-11 | 2014-10-09 | Genzyme Corporation | Hyperglycosylated binding polypeptides |
| JP2015516401A (ja) * | 2012-04-24 | 2015-06-11 | シアトル ジェネティックス, インコーポレイテッド | Dr5リガンド薬物コンジュゲート |
| JP2015521187A (ja) * | 2012-05-15 | 2015-07-27 | シアトル ジェネティクス,インコーポレイティド | 自己安定化リンカー結合体 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2981731A (en) | 1961-04-25 | Acridine derivatives | ||
| US2985661A (en) | 1956-02-06 | 1961-05-23 | American Cyanamid Co | Preparation of 2(omicron-aminophenyl)-benzimidazole |
| US2915523A (en) | 1956-12-03 | 1959-12-01 | Parke Davis & Co | Benzacridine compounds |
| US3272707A (en) | 1964-07-17 | 1966-09-13 | Smith Kline French Lab | Pharmaceutical compositions and methods for their use |
| CH420045A (de) | 1964-09-01 | 1967-03-15 | Ciba Geigy | Verwendung von neuen Poly-azolen als optische Aufhellmittel für textile organische Materialien |
| US3267107A (en) | 1964-09-17 | 1966-08-16 | American Home Prod | 3-(4'-5'-methylenedioxy-phenyl)-7, 8-dimethoxy-1, 2, 3, 4,-tetrahydroisoquinolines |
| US3849561A (en) | 1964-10-20 | 1974-11-19 | S Naruto | Anti-peptic ulcer substance from corydalis tubers |
| DE1670684A1 (de) | 1966-04-01 | 1970-12-03 | Hoechst Ag | Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten |
| US3542782A (en) | 1967-03-15 | 1970-11-24 | Sandoz Ag | 5,6-dihydro-8h-isoquino(1,2-b)quinazolines |
| JPS4942700A (cg-RX-API-DMAC7.html) | 1972-08-25 | 1974-04-22 | ||
| US3912740A (en) | 1974-02-28 | 1975-10-14 | Us Health | Method for the preparation of oxygenated benzo{8 c{9 phenanthridine compounds |
| PT73763B (fr) | 1981-10-01 | 1983-10-26 | Quatrum Empresa Nacional De Qu | Procede pour la preparation de nouveaux epoxides d'alkaloides benzofenantridiniques et de compositions pharmaceutiques qui les contiennent |
| US5153178A (en) | 1982-05-14 | 1992-10-06 | Maroko Peter R | Compositions and method of treatment for improving circulatory performance |
| IE55519B1 (en) | 1982-05-14 | 1990-10-10 | Maroko Peter R | Use of a protoberberine alkaloid and composition containing same |
| US4749708A (en) | 1982-05-14 | 1988-06-07 | Maroko Peter R | Composition for improving circulatory performance |
| US4980344A (en) | 1982-05-14 | 1990-12-25 | Maroko Peter R | Compositions for improving circulatory performance |
| US4761417A (en) | 1982-05-14 | 1988-08-02 | Maroko Peter R | Compounds, compositions and method of treatments for improving circulatory performance |
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| JPS61130289A (ja) | 1984-11-29 | 1986-06-18 | Ss Pharmaceut Co Ltd | 13−プロピルベルベリンの塩 |
| FR2595356B1 (fr) | 1986-03-05 | 1991-05-24 | Pasteur Strasbourg Universite | Derives des nitro ou aminobenzyltetrahydroisoquinoleines, procedes d'obtention, compositions pharmaceutiques les contenant, proprietes pharmacologiques et applications |
| US5244903A (en) | 1987-03-31 | 1993-09-14 | Research Triangle Institute | Camptothecin analogs as potent inhibitors of topoisomerase I |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| SU1530628A1 (ru) | 1987-11-20 | 1989-12-23 | Ленинградский Технологический Институт Им.Ленсовета | Тригидрохлорид 2-[2-фенил-5(6)-бензимидазолил]-N-(3-диметиламинопропил)-5(6)-бензимидазолкарбоксамида в качестве флуоресцентного красител дл исследовани ДНК |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| US5106863A (en) | 1990-03-26 | 1992-04-21 | Ortho Pharmaceutical Corporation | Substituted imidazole and pyridine derivatives |
| US5135934A (en) | 1990-07-06 | 1992-08-04 | Du Pont Merck Pharmaceutical Company | 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents |
| US5126351A (en) | 1991-01-24 | 1992-06-30 | Glaxo Inc. | Antitumor compounds |
| US5223506A (en) | 1991-06-04 | 1993-06-29 | Glaxo Inc. | Cyclic antitumor compounds |
| US5428040A (en) | 1993-08-31 | 1995-06-27 | The Du Pont Merck Pharmaceutical Company | Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents |
| DE69430752T2 (de) | 1993-09-28 | 2002-10-17 | Kyowa Hakko Kogyo Co., Ltd. | Tetracyclische verbindungen |
| US5807874A (en) | 1995-05-17 | 1998-09-15 | Rutgers, The State University Of New Jersey | Trisbenzimidazoles useful as topoisomerase I inhibitors |
| CA2221248A1 (en) | 1995-05-17 | 1996-11-21 | Leroy Fong Liu | Tribenzimidazoles useful as topoisomerase i inhibitors |
| US5767142A (en) | 1996-03-20 | 1998-06-16 | Rutgers, The State University Of New Jersey | Trisbenzimidazoles useful as topoisomerase I inhibitors |
| PL328402A1 (en) | 1996-02-12 | 1999-01-18 | Rutgers | Analoques of coralline as inhibitors of topoisomerase |
| US5770617A (en) | 1996-03-20 | 1998-06-23 | Rutgers, The State University Of New Jersey | Terbenzimidazoles useful as antifungal agents |
| BR9711296A (pt) | 1996-09-23 | 1999-08-17 | Univ Rutgers | Composto processo terap-utico para inibir o crescimento de c-lulas de c ncer e composi-Æo farmac-utica |
| US6140328A (en) | 1997-12-12 | 2000-10-31 | Rutgers, The State University Of New Jersey | Heterocyclic cytotoxic agents |
| WO2000021537A1 (en) | 1998-10-14 | 2000-04-20 | Purdue Research Foundation | Novel indenoisoquinolines as antineoplastic agents |
| WO2001032631A2 (en) | 1999-10-29 | 2001-05-10 | Rutgers, The State University Of New Jerey | Heterocyclic cytotoxic agents |
| US6740650B2 (en) | 1999-10-29 | 2004-05-25 | Rutgers, The State University Of New Jersey | Heterocyclic cytotoxic agents |
| CA2467279A1 (en) | 2001-11-14 | 2003-06-26 | Edmond J. Lavoie | Solubilized topoisomerase poison agents |
| DE60225943T2 (de) | 2001-11-14 | 2009-01-29 | Rutgers, The State University | Topoisomerase-giftmittel |
| ATE405568T1 (de) | 2001-11-14 | 2008-09-15 | Univ Rutgers | Cytotoxische mittel |
| AU2002363658B2 (en) | 2001-11-14 | 2008-09-11 | Rutgers, The State University | Solubilized topoisomerase poisons |
| US6989387B2 (en) | 2002-08-09 | 2006-01-24 | Rutgers, The State University Of New Jersey | Nitro and amino substituted topoisomerase agents |
| AU2003268075A1 (en) | 2002-08-09 | 2004-02-25 | Edmond J. Lavoie | Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents |
| US6992088B2 (en) | 2002-08-09 | 2006-01-31 | Rutgers, The State University Of New Jersey | Nitro and amino substituted heterocycles as topoisomerase I targeting agents |
| AU2003290818A1 (en) | 2002-11-12 | 2004-06-03 | Edmond J. Lavoie | Topoisomerase-targeting agents |
| ZA200800314B (en) | 2005-06-29 | 2009-09-30 | Threshold Pharmaceuticals Inc | Phosphoramidate alkylator prodrugs |
| TW201038578A (en) | 2009-01-30 | 2010-11-01 | Univ Rutgers | Methods to treat cancer |
| JP5773888B2 (ja) | 2009-03-06 | 2015-09-02 | ラットガーズ,ザ・ステート・ユニバーシティ・オブ・ニュージャージー | 癌治療に用いられるメチレンジオキシベンゾ[i]フェナントリジン誘導体 |
-
2017
- 2017-04-03 EP EP17779604.2A patent/EP3442979A4/en not_active Withdrawn
- 2017-04-03 WO PCT/US2017/025779 patent/WO2017176648A1/en not_active Ceased
- 2017-04-03 JP JP2019502543A patent/JP2019515025A/ja active Pending
- 2017-04-03 CA CA3019945A patent/CA3019945A1/en active Pending
- 2017-04-03 US US16/090,802 patent/US11091498B2/en active Active
- 2017-04-03 CN CN201780034468.4A patent/CN109219610A/zh active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007514652A (ja) * | 2003-11-06 | 2007-06-07 | シアトル ジェネティックス, インコーポレイテッド | リガンドに結合体化可能なモノメチルバリン化合物 |
| WO2006065448A2 (en) * | 2004-11-18 | 2006-06-22 | Threshold Pharmaceuticals, Inc. | Topoisomerase inhibitors and prodrugs |
| JP2010519310A (ja) * | 2007-02-21 | 2010-06-03 | メダレックス インコーポレイテッド | 単一のアミノ酸を有する化学リンカーおよびその複合体 |
| JP2010526821A (ja) * | 2007-05-08 | 2010-08-05 | ジェネンテック, インコーポレイテッド | システイン改変抗muc16抗体および抗体−薬物結合体 |
| WO2010127363A1 (en) * | 2009-05-01 | 2010-11-04 | Rutgers, The State University Of New Jersey | Toposiomerase inhibitors |
| JP2015516401A (ja) * | 2012-04-24 | 2015-06-11 | シアトル ジェネティックス, インコーポレイテッド | Dr5リガンド薬物コンジュゲート |
| JP2015521187A (ja) * | 2012-05-15 | 2015-07-27 | シアトル ジェネティクス,インコーポレイティド | 自己安定化リンカー結合体 |
| WO2014164503A1 (en) * | 2013-03-11 | 2014-10-09 | Genzyme Corporation | Hyperglycosylated binding polypeptides |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3442979A4 (en) | 2019-12-18 |
| WO2017176648A1 (en) | 2017-10-12 |
| EP3442979A1 (en) | 2019-02-20 |
| CN109219610A (zh) | 2019-01-15 |
| US20200325149A1 (en) | 2020-10-15 |
| CA3019945A1 (en) | 2017-10-12 |
| US11091498B2 (en) | 2021-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11497757B2 (en) | Silanol based therapeutic payloads | |
| JP6824931B2 (ja) | 第3級アミン含有薬物物質の標的送達 | |
| EP0673258B1 (en) | Polymer-bound camptothecin derivatives | |
| US20090246211A1 (en) | Molecular constructs suitable for targeted conjugates | |
| CA3099421A1 (en) | Compounds comprising a linker for increasing transcyclooctene stability | |
| JP2018507844A (ja) | 抗体薬物コンジュゲート | |
| KR20250150111A (ko) | 캄프토테신 유도체 및 이의 접합체, 이의 제조 방법 및 의학적 용도 | |
| CA3210473A1 (en) | Branched linkers for antibody-drug conjugates and methods of use thereof | |
| US12343399B2 (en) | Polymer linkers and their uses | |
| AU2012275953B2 (en) | Acid-labile lipophilic prodrugs of cancer chemotherapeutic agents | |
| EP2740493A1 (en) | Conjugates of the B-subunit of Shiga toxin for anticancer therapies | |
| US11091498B2 (en) | Topoisomerase poisons | |
| US9321781B2 (en) | Topoisomerase inhibitors | |
| KR102346268B1 (ko) | 경구 항암 전구약물을 포함하는 복합체, 이의 제조방법 및 이의 용도 | |
| EP4674840A1 (en) | Chemical coupling linker and use thereof | |
| CA3026434C (en) | Polymer linkers and their uses | |
| KR20250125737A (ko) | 항체-약물 접합체에 사용하기 위한 신규 약물-링커 화합물 | |
| KR20240016231A (ko) | 신규 오리스타틴 전구약물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190411 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200331 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200331 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210210 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210302 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210526 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20211102 |